of incomplete understanding of its pathophysiology and the lack of effective therapeutic strategies. The progression of renal fibrosis is considered to be a common process that eventually leads to end-stage renal disease, necessitating dialysis or renal transplantation (1) (2) (3) . Irrespective of the initial cause(s), the striking feature of tubulointerstitial fibrosis is the activation of smooth muscle α-actin (α-SMA)-positive myofibroblasts, which are thought to be the central effectors responsible for extracellular matrix (ECM) deposition and scar tissue formation in renal disease (4) (5) (6) . Although multiple sources are proposed (7) (8) (9) , lineage analyses show that resident mesenchymal fibroblasts are the myofibroblast progenitor pool during fibrosis (10) . Therefore, interstitial fibroblast activation remains a very important pathway leading to the generation of ECM-producing myofibroblasts.
Transforming growth factor-β (TGF-β) and its intermediate Smad signaling proteins are viewed as the premier fibrosis-promoting molecules and play major roles in the pathogenesis of renal fibrosis (1, (11) (12) (13) (14) (15) (16) (17) . However, the downstream targets mediating the fibrogenic effect of TGF-β remain largely unknown. Response gene to complement 32 (RGC-32) is a TGF-β downstream target (18, 19) . The present study was designed to investigate the potential role of RGC-32 in renal fibrosis following unilateral ureteral obstruction (UUO), a model of kidney disease with progressive tubulointerstitial fibrosis. Our results show that UUO causes structural damage and collagen deposition along with increased expression of RGC-32 in kidney interstitial cells at the early stage of the injury. Blockade of RGC-32 expression significantly attenuates UUO-induced renal damage, ECM production, and expression of myofibroblast marker. Studies using mesenchymal and kidney fibroblasts indicate that RGC-32 induces fibroblast activation in vitro. Additional studies demonstrate that RGC-32 interacts with Smad3 to enhance its binding to α-SMA promoter, thus regulate Smad3 induction of myofibroblast marker transcription. Together, our results have identified RGC-32 as a novel fibrogenic factor contributing to the onset of renal tubulointerstitial fibrosis.
EXPERIMENTAL PROCEDURES
Experimental Animals and Design─ All surgeries were performed according to protocols overseen by the Institutional Animal Care and Use Committee (IACUC) of Georgetown University. Male C57BL6/J mice, weighing 20-25 g at the start of the experiment, were anesthetized with pentobarbital and tracheotomized. UUO was achieved by doubleligating the left ureter with 3-0 silk through a left lateral incision. Sham-operated animals (n = 5) were used as controls. Mice were sacrificed at 3, 5, 7, 10, or 15 days (for each group, n = 5) after the UUO, and the obstructed kidneys were harvested and subjected to the studies described below.
In vivo delivery of shRNA and expression plasmid─ shRNA is constructed in pGeneClip vector (Promega). The delivery was performed by injection of scrambled or RGC-32 shRNA plasmids through the renal artery using the In Vivo Gene Delivery System (Mirus). The mice were anesthetized with pentobarbital (50mg/Kg body wt). The femoral and abdominal areas of the mice were shaved and treated with chlorhexidine as described in UUO model. The abdominal aorta was exposed via a midline abdominal incision. The left femoral artery was exposed by an inguinal incision on the ventral side of the left thigh. Using a stereomicroscope, a PE-10 catheter, heat-stretched to 180 micra, was inserted into the femoral artery (through an appropriately sized incision) and pushed inside the abdominal aorta to a position just above the left renal artery but below the right renal artery. This position was verified by gently lifting the vessel using a small forceps. This procedure allowed the selective and exclusive delivery of reagents into the left kidney. The abdominal aorta was clamped below the right renal artery and below the left renal artery, to ensure delivery of the reagents only into the left kidney. In our preliminary studies, the clamping procedure did not affect renal function or histology. After the injection of the reagents in a 200 l solution (with lissamine green) in 20 seconds using a 1 ml tuberculin syringe, the catheter was carefully retracted. The left ureter was then sham-or double-ligated to generate UUO. The incision on the femoral artery was repaired using 11-0 silk sutures and the skin incisions closed.
Histopathological and Immunohistochemical
Analyses─ Kidney tissues were fixed in 4% paraformaldehyde in 1xPBS and embedded in paraffin. Tissue sections (5 μm thick) were stained with H&E or Masson's trichrome staining for histopathological analysis. Immunoreactivity for RGC-32, α-SMA, collagen I and fibronectin was determined by using standard immunohistochemistry staining. The primary antibodies were rabbit anti-RGC-32 (19) , monoclonal mouse anti-α-SMA (Sigma), mouse anti-collagen I and fibronectin (Abcam). The secondary antibody was affinity-purified goat anti-rabbit or goat anti-mouse IgG (Cell Signaling). Nuclei were counterstained lightly with hematoxylin. Masson's trichrome staining─ Masson's staining was performed using a Masson's trichrome staining kit (DAKO), following the standard procedure.
Cell culture, transfection and luciferase assay─ C3H10T1/2 and NRK-49F cells were cultured as previously described (20) (21) (22) . Cells were transiently transfected (in triplicate) with LipofectAMINE LTX plus reagents (Invitrogen), and luciferase assay was performed as described (20, 21) . Reverse Transcription-PCR (RT-PCR) and quantitative PCR (qPCR)─ Total RNA was extracted using TRIzol reagent (Invitrogen) following the manufacturer's instruction. cDNA was synthesized using an iScript cDNA synthesis kit (Bio-Rad). RT-PCR was performed using Bio-Rad C1000 thermal cycler. qPCR was performed in MX3000P qPCR machine using SYBR Green qPCR Mastermix (Agilent). The primers used in PCR were described previously (19) . Western blotting─ Fibroblasts or kidney tissues were lysed or homogenized in RIPA lysis buffer (1% NP40, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 1 mM sodium orthovanadate, and protease inhibitors in PBS). Samples were separated on SDS-polyacrylamide gels, and electrotransferred onto nitrocellulose membranes (Amersham). The membranes were incubated for 16 h at 4°C with various primary antibodies in blocking buffer containing 5% milk followed by incubation with HRP-conjugated secondary antibody (Bio-Rad). Co-immunoprecipitation (co-IP) assay─ was performed as described (23, 24) . DNA affinity assay─ DNA-protein binding assay was performed as described (25, 26) . Briefly, 5 µg of biotin-labeled double-strand oligonucleotides and 500 ng of Smad3, Smad4 (SignalChem), and/or RGC-32 proteins were incubated in a binding buffer (0.1% Triton X-100, 4% glycerol, 1 mM EDTA, 10 mM DTT, 10 mM Tris) at 37 ℃ for 1 h. Streptavidincoated agarose beads (Sigma) were then added followed by end-over-end rotation at 4 ℃ overnight. The agarose beads were pelleted and washed with cold 1xPBS for 3 times, and proteins bound to the beads were eluted and immunoblotted with Smad3, Smad4 or RGC-32 antibodies. RGC-32 proteins were obtained by expression of pETDuet-1-RGC32 in E. Coli and purified by His-Spin Protein Miniprep kit (Zymo Research). pETDuet-1-RGC32 was cloned by insertion of full-length mouse RGC-32 cDNA into pETDuet-1 expression vector at BamHI/SalI sites. The cDNA insertion was verified by sequencing and the purity of RGC-32 protein was verified by Coomassie Blue staining and western blot using RGC-32 antibody. The biotin-labeled oligonucleotides used in the DNA affinity assay were from the rat α-SMA promoter region with SBE (26) . The sense strand sequences for wild type and mutant oligonucelotides were: SBE: 5'-ACA GAC TTC ATT GAT ACT ACA CAC AGA CTC CAG ACT AC-3', SBE mutant: 5'-TAC AGA CTT CAT TGA TAC TAC ACA aAG ctT CCA GAC-5'.
Chromatin immunoprecipitation assay (ChIP)─ ChIP assays were performed as described previously (24, 27) . NRK-49F cells were treated with vehicle or TGF-β for 24 hr followed by additional 1 hr of treatment with new TGF-β to induce Smad nuclear translocation. Chromatin complexes were immunoprecipitated with 3 µg of Smad2 or Smad3 antibody or IgG (negative control). Semi-quantitative PCR and/or qPCR were performed to amplify the α-SMA promoter region containing the functional Smad binding site using the following primer set: 5'-CAT GCA CGT GGA CTG TAC CT-3' (forward) and 5'-AAA GAT GCT TGG GTC ACC TG-3' (reverse) (26) . The primers for amplifying the SBE region for the PAI-1 promoter were: 5'-CTC TGT GAT GGC TGT CTC CA-3' (forward) and 5'-CTT CCC TCC CTC CCA GTA AC-3' (reverse) (28) .
Statistical analysis─ All values are expressed as mean±SEM. Data were analyzed using ANOVA with pairwise comparisons between groups. A level of P<0.05 was considered statistically significant.
RESULTS

RGC-32 is induced along with the progression of renal fibrosis in kidneys with UUO.
In order to determine if RGC-32 is involved in the pathogenesis of renal fibrosis, we first determined if RGC-32 expression in kidney is altered by UUO. RGC-32 was found to be expressed in mouse kidney (29) , but precisely which cells express RGC-32 has not been determined. We found that RGC-32 was expressed only in smooth muscle cells (SMC) of blood vessels in the normal mouse kidney as indicated by α-SMA staining (Fig 1A-IV) . 5 days after the UUO, RGC-32 was strongly induced in the tubulointerstitium (Fig 1A-V) . Importantly, α-SMA expression was also limited to the interstitial cells of obstructed kidney at this early stage (Fig 1A-VIII) , suggesting that RGC-32 plays a role in the activation of myofibroblasts from resident fibroblasts. By 15 days after the UUO, RGC-32 and α-SMA were extensively expressed in both kidney interstitium and tubules ( Fig 1A-VI and IX). At this time point, severe kidney structural damages including glomeruli atrophy, tubule dilation and atrophy, inflammatory cell infiltration, and extensive interstitial fibrosis were observed (Fig 1A-III) . These results indicate that RGC-32 is induced along with myofibroblast activation by UUO. To examine the dynamics of RGC-32 expression induced by progressive injury due to UUO, kidney proteins were extracted 5, 10 and 15 days after the UUO and blotted with RGC-32 and α-SMA antibodies. As shown in Fig 1B, both RGC-32 and α-SMA were significantly upregulated 5 days after UUO. The expression increased with the duration of UUO. It appeared that RGC-32 expression reached the highest level at 10 days after UUO and remains unchanged at 15 days after UUO. Interestingly, the expression of α-SMA correlated with the activation of RGC-32 ( Fig 1C) .
RGC-32 knockdown attenuates the fibroblast activation in vivo.
To test if RGC-32 plays a role in the pathogenesis of renal fibrosis, we developed a method to infuse RGC-32 shRNA into mouse kidney through renal artery using an In Vivo Gene Delivery System. Using this method, we infused control or RGC-32 shRNA into mouse left kidneys followed by UUO for 10 days. As shown in Fig 2A, shRNA knockdown of UUO-induced RGC-32 expression blocked α-SMA expression in the interstitial cells (Fig 2A-II and IV). RGC-32 shRNA did not block RGC-32 or α-SMA expression in SMC of the blood vessels (Fig 2A-II and IV) because SMC in the blood vessels normally expresses a significant amount of RGC-32 protein before UUO operation (Fig 1A-IV) . It is known that shRNA only degrades the newly synthesized mRNA but does not affect pre-existing proteins. Quantitative analyses show that UUO kidneys with control shRNA strongly expressed RGC-32 and α-SMA proteins (Fig 2B and 2C) . However, RGC-32 shRNA, which blocked the expression of RGC-32 with an 80% knockdown efficiency, caused a 50% reduction of α-SMA expression induced by UUO (Fig 2C) . These data demonstrate that RGC-32 is essential for myofibroblast activation in kidney interstitium in the onset or progression of UUO-induced renal fibrosis.
Blockade of RGC-32 inhibits ECM deposition in mouse kidneys with UUO.
Excessive synthesis and accumulation of ECM proteins in kidney interstitium is a hallmark of renal tubulointerstitial fibrosis, as seen in obstructive nephropathy. ECM deposition results in kidney structural damage and functional impairment. To determine if RGC-32 plays a role in ECM deposition as well as structural damage induced by UUO, we observed kidney structural alteration by H&E staining and examined the expression of collagen I by Masson's trichrome staining and western blot in kidneys infused with control or RGC-32 shRNA. Structurally, UUO caused dilatation of renal tubules, denudation of basement membranes, and interstitial expansion, consistent with previous reports (30) (Fig 3A-II) . RGC-32 knockdown by shRNA, however, significantly reduced UUO-induced damage. RGC-32 shRNA restored the normal structure of proximal tubules and eliminated the interstitial expansion (Fig 3A-III) . These data suggest that RGC-32 contributed, at least in part, to the structural damage in the progressive nephropathy.
RGC-32 appears to be important for ECM production in UUO-induced nephropathy. Compared to sham-operated mice, UUO induced a significant amount of collagen accumulation in kidney tubulointerstitium (Fig 3A-V) . RGC-32 shRNA, however, significantly inhibited the accumulation of collagen (Fig 3A-VI) in kidney interstitium. Western blot showed that UUO induced a significant increase in collagen I expression in the kidney 10 days after the UUO. RGC-32 knockdown, however, significantly blocked collagen I expression (Fig 3B and 3C ). These data demonstrate that RGC-32 is required for collagen I synthesis and accumulation in the renal interstitium in obstructive nephropathy.
RGC-32 is important for fibroblast activation.
Although myofibroblasts may originate from several sources including resident mesenchymal fibroblasts, epithelial cells via EMT, endothelial cells via endothelial-mesenchymal transition, and circulating fibroblast-like cells called fibrocytes derived from bone-marrow stem cells (7-9), interstitial resident mesenchymal fibroblast activation remains one of the important pathways leading to the generation of ECM-producing myofibroblasts. UUO induced interstitial expression of both RGC-32 and α-SMA in mouse kidneys, especially in the early stages of obstructive nephropathy (Fig 1A-V, VIII) , suggesting that the α-SMA-producing myofibroblasts were derived from interstitial fibroblasts.
TGF-β, which is activated in kidneys three days after UUO, plays a central role in activating fibroblasts in renal fibrosis (2, 31, 32) . Since RGC-32 is a TGF-β downstream target (18, 19) and is important for the generation of myofibroblasts in the kidney with UUO (Figs 2 and 3) , we hypothesize that RGC-32 is induced by TGF-β during myofibroblast activation from mesenchymal fibroblasts. To test this hypothesis, we used C3H10T1/2 (10T1/2) mesenchymal progenitor cells (Fig 4A-4B and 4D) ) and kidney fibroblast NRK-49F cells (Fig 4C) as models to study the induction of myofibroblasts by TGF-β. As shown in Fig 4A-4C , TGF-β induced myofibroblast differentiation of 10T1/2 and NRK-49F cells as indicated by the expression of myofibroblast marker genes α-SMA and collagen I. TGF-β also induced RGC-32 expression during the fibroblast activation (Fig 4A-4C) . The induction of RGC-32 occurred as early as 2 h after TGF-β induction (Fig 4A) , suggesting that RGC-32 plays a role in TGF-β-induced fibroblast activation.
To test if RGC-32 is important for TGF-β-induced fibroblast activation, we expressed control or RGC-32 shRNA in 10T1/2 ( Fig 4B) and NRK-49F cells (Fig 4C) and then treated the cells with TGF-β for 24 h and studied the effect of RGC-32 knockdown on myofibroblast markers. Control shRNA did not affect the expression of RGC-32 and myofibroblast markers in TGF-β-treated cells. RGC-32 shRNA, however, significantly inhibited TGF-β-induced expression of RGC-32 as well as α-SMA and collagen I (Fig  4B-4C) . These results indicate that RGC-32 is essential for TGF-β-induced fibroblast activation. To determine if RGC-32 alone induces fibroblast activation, RGC-32 cDNA was transfected in 10T1/2 cells; and myofibroblast marker gene expression was examined. Interestingly, RGC-32 by itself was sufficient to induce the expression of myofibroblast markers (Fig 4D) .
RGC-32 physically interacts with both Smad3
and Smad2. TGF-β function is mediated by both Smad2 and Smad3. In fibroblasts, it appears that Smad3, but not Smad2, is important for the activation of α-SMA promoter activity (20, 33) . TGF-β-induced collagen type I and III expression is ablated in Smad3 knockout (KO) mouse embryo fibroblasts (MEF), but not in the Smad2 KO MEF (15) . Although Smad2 is also involved, Smad3 appears to play a major role in activating fibroblasts and fibrosis (15) (16) (17) 20, 33) . Since RGC-32 and Smad3 are both involved in regulating the promoter activity of myofibroblast marker α-SMA in different cells (18, (34) (35) (36) , we hypothesized that RGC-32 interacts with Smad3 to induce fibroblast activation. To test if RGC-32 and Smad3 physically interacts, Co-IP was performed by overexpressing RGC-32, Smad2 and Smad3 individually or in combination in 10T1/2 cells. As shown in Fig 5A, RGC-32 strongly interacted with Smad3, but slightly with Smad2 in 10T1/2 cells. To confirm these interactions, Co-IP was performed using endogenous proteins extracted from 10T1/2 cells. Interestingly, as shown in Fig 5B and 5C , RGC-32 appeared to interact with both Smad2 and Smad3 (left panels of Fig 5B and 5C ). These interactions were specific because shRNA knockdown of Smad2 or Smad3 diminished the Co-IP between RGC-32 and Smad2 or Smad3 (Fig 5B and 5C, right panels) .
RGC-32 enhances Smad3 binding to Smad binding element (SBE) in the promoters of fibroblast activation-related genes.
Smad3 regulates α-SMA gene transcription through binding to SBE in the α-SMA promoter (35) . In order to test if Smad2 or Smad3 interacts with SBE in α-SMA promoter in a chromatin setting in kidney fibroblasts, CHIP assays were performed. We found that Smad3, but not Smad2, bound the functional SBE in α-SMA promoter in vivo in kidney fibroblasts (Fig 6A) . Since RGC-32 interacts with Smad3, we sought to determine if RGC-32 plays a role in Smad3 interaction with α-SMA promoter in vivo. Adenoviral vector expressing GFP or RGC-32 shRNA was transduced into NRK-49F cells followed by vehicle or TGF-β treatment. Endogenous Smad3 binding to SBE in α-SMA promoter was assessed by CHIP assay. We found that TGF-β induced an enhanced binding of Smad3 to α-SMA promoter (Fig 6B and 6C) . RGC-32 knockdown, However, significantly blocked TGF-β-enhanced Smad3 interaction with the promoter (Fig 6B and 6C) , suggesting that RGC-32 is essential for Smad3 binding to SBE in α-SMA promoter in kidney fibroblasts, thus regulating Smad3-mediated α-SMA promoter activity.
To determine if RGC-32 enhances Smad3 interaction with promoters of other fibroblast activation-related genes, we tested Smad3 binding to the SBE in the promoter of plasminogen activator inhibitor-1 (PAI-1). PAI-1 plays an important role in fibroblast activation and renal fibrosis (37) . As shown in Fig 6D and  6E , similar to α-SMA promoter, TGF-β increased the Smad3 binding to SBE of PAI-1 promoter, shRNA knockdown of RGC-32, however, significantly inhibited Smad3 binding. These results suggest that RGC-32 is crucial for Smad3 interaction with promoters of multiple fibroblast activation genes. RGC-32 increases the affinity of Smad3 binding to α-SMA promoter. In order to further determine the role of RGC-32 in Smad3 interaction with α-SMA promoter, we performed DNA affinity assay with purified Smad3, Smad4 and RGC-32 proteins and biotin-labeled DNA oligonucleotides containing wild type or mutant SBE. Smad3 bound to α-SMA in a dose-dependent manner; SBE mutation diminished the binding (Fig 7A) . Both Smad4 and RGC-32 enhanced the Smad3 binding to the SBE site (Fig 7 B and 7C) . Importantly, combination of RGC-32 and Smad4 further increased the Smad3 binding (Fig 7 B and  7C ), demonstrating that RGC-32 is able to increase the Smad3 binding affinity to α-SMA promoter with or without the presence of Smad4.
RGC-32 plays an essential role in Smad3-mediated activation of myofibroblast marker gene transcription. To determine if RGC-32-mediated
Smad3 binding to α-SMA promoter plays a role in fibroblast activation, we tested if RGC-32 affects Smad3-induced α-SMA promoter activity in both 10T1/2 ( Fig 8A) and NRK-49F cells ( Fig  8B) . We found that only Smad3, but not Smad2, significantly increased α-SMA promoter activity in both cells (Fig 8) , consistent with their role in renal fibrosis (15) (16) (17) 20, 33) . Smad3-induced promoter activity was diminished, however, by RGC-32 shRNA in both mesenchymal (Fig 8A) and kidney fibroblasts (Fig 8B) , demonstrating that RGC-32 is required for Smad3 function in inducing fibroblast activation. RGC-32 shRNA also reduced α-SMA promoter activity in control (Fig 8B) or Smad2-transfected cells (Fig 8A and  8B ), but this effect is likely due to the interruption of endogenous RGC-32/Smad3 interaction by RGC-32 shRNA. It was not an effect on Smad2 activity because Smad2 did not increase α-SMA promoter activity (Fig 8) . These data demonstrate that RGC-32 enhances Smad3 binding, and thus activates the promoters of myofibroblast marker genes to mediate TGF-β-induced fibroblast activation, which may lead to the generation of myofibroblasts in kidney interstitium when the mouse is subjected to progressive injury as seen in obstructive injury and UUO.
DISCUSSION
Emerging evidence indicates that TGF-β is a key mediator in the progression of renal fibrosis (38) . Tubulointerstitial fibrosis is an inevitable common pathway of chronic kidney diseases (CKD) resulting from many disorders, including hypertension, diabetes, infection, inflammation, kidney stones, and cysts (39) . The extent of tubulointerstitial damage correlates with renal prognosis (40). Therefore, elucidation of the pathogenetic mechanisms involved in the progression of tubulointerstitial fibrosis is important for designing a strategy to prevent progressive kidney diseases leading to end-stage renal failure. Many studies have shown that TGF-β signaling intermediate Smad proteins including Smad3, Smad4 and Smad7 play important roles in the progression of renal fibrosis (16, 41, 42) . However, the downstream targets essential for the onset of the fibrosis especially fibroblast activation, however, remain largely unknown.
RGC-32, a complement-activated gene, was identified as a TGF-β downstream target, which plays an important role in smooth muscle differentiation from neural crest cells (18) . RGC-32 is also involved in the EMT of renal epithelial cells in vitro (19) . Since the relative contribution of EMT to renal fibrosis is still being debated (43), RGC-32-induced EMT may not contribute to the development of renal fibrosis in vivo. Indeed, our data show that RGC-32 is mainly induced in interstitial cells in mouse kidneys with UUO, especially in the early stage of renal fibrosis. The induction correlates with the expression of myofibroblast marker α-SMA (Fig  1) , suggesting a role of RGC-32 in fibroblast activation in the kidney interstitium. Knockdown of RGC-32 by shRNA significantly attenuates the expression of both RGC-32 and α-SMA after 10 days of UUO (Fig 2) , demonstrating that RGC-32 is essential for fibroblast activation. Knockdown of RGC-32 also ameliorates kidney structural damage and ECM deposition in the kidney interstitium caused by UUO, suggesting that RGC-32 may be an ideal target for reversing the progression of renal fibrosis. Although RGC-32 is also expressed in renal tubules at the later stages of fibrosis, e.g., 15 days after UUO, the EMT events of the tubule cells such as migration and invasion are not evident in kidneys with UUO (44) . Therefore, the role of RGC-32 in EMT of renal tubule cells in vivo can only be determined after the EMT mechanism in the obstructive nephropathy is well-defined. RGC-32 is important for fibroblast activation in both mesenchymal and kidney fibroblasts. RGC-32 knockdown by shRNA blocks TGF-β-induced marker gene expression (Fig 4B and 4C) . Mechanistically, RGC-32 appears to partner with Smad3 to regulate fibroblast activation. It is well documented that Smad3 is critical for the induction of renal fibrosis (16, 42, 45) . RGC-32 shares several common characteristic with Smad3. Both of RGC-32 and Smad3 are TGF-β downstream effectors important for fibroblast activation (Fig 4)  (15-17,20,33) ; both are nuclear proteins regulating the same myofibroblast marker genes such as α-SMA (18, 20, 29, 33) ; and both play roles in renal fibrosis. These observations suggest that RGC-32 interacts with Smad3 in activating fibroblasts. Indeed, RGC-32 physically interacts with Smad3 (Fig 5) . Although RGC-32 also interacts with Smad2, Smad2 does not bind to α-SMA promoter and is not involved in TGF-β-induced fibroblast activation (Fig 6A and 8) .
RGC-32 appears to induce fibroblast activation through enhancing Smad3 binding to SBE of myofibroblast marker genes. Smad3, but not Smad2, binds to the SBE of α-SMA promoter. TGF-β enhances Smad3 binding. TGF-β-induced Smad3-SBE interaction requires RGC-32 because knockdown of RGC-32 attenuates Smad3 binding to α-SMA promoter in vivo. In addition to α-SMA, RGC-32 also increases Smad3 binding to PAI-1 promoter, suggesting that RGC-32 may regulate several different fibroblast activationrelated genes via enhancing Smad3 binding to SBE in their promoters. Importantly, RGC-32 appears to increase Smad3 binding affinity independent of Smad4 because RGC-32 is able to enhance Smad3 binding to SBE of α-SMA promoter in the absence of Smad4. In the presence of Smad4, RGC-32 can further increase Smad4-enhanced Smad3 binding. Functionally, RGC-32 is essential for TGF-β-induced α-SMA promoter activation in fibroblasts. Smad3 is required for TGF-β function in activating the promoter, but Smad3 function is dependent on RGC-32 because RGC-32 knockdown blocks Smad3-mediated promoter activity (Fig 8) , suggesting that RGC-32 functionally interacts with Smad3 in the activation of α-SMA promoter.
In conclusion, we have identified RGC-32 as a novel fibrogenic factor in the progression of renal fibrosis in obstructive nephropathy in UUO model. We have also demonstrated that RGC-32 mediates TGF-β-induced fibroblast activation by interacting with Smad3, leading to an enhanced Smad3 binding to SBE, which activate the transcription programs of myofibroblast marker genes. 
